Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising
Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...
712 Views
Cybersecurity and ESG: Beyond the Breach
Cybercrime is the greatest threat to every company in the world. – Ginni...
663 Views
U. S. Equity Strategy: Small-Caps Closing the Gap
Major averages in the US (S&P 500, Dow, Russell 2000) and Europe (STOXX 600 & 50) each had throwbacks to their prior breakout levels last...
521 Views
ECM Weekly (3 Aug 2019) - Sterling&Wilson, Spandana Sphoorty, Smoore, AllHome, JS Global
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
937 Views
Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi
Last night, Merck & Co Inc. (MRK US) announced that its Keytruda hits primary endpoint in Phase III (KEYNOTE-522) clinical trial in the...
647 Views